Tag Archives: peritoneal mesothelioma

Misdiagnosis of Mesothelioma More Common with Cytology Alone

misdiagnosis of mesothelioma

A new set of case reports illustrates how easily misdiagnosis of mesothelioma can happen when the diagnosis is based on cytology alone.  Cytology tests look at the cells in body fluids. For peritoneal mesothelioma patients, this is often the fluid that collects in their abdomen called ascites.  But doctors from India’s Dayanand Medical College and Hospital say using ascites samples alone to diagnose mesothelioma is a risky practice. Misdiagnosis of mesothelioma may delay proper treatment and negatively impact survival. The Difficulty of Diagnosing Peritoneal Mesothelioma Malignant mesothelioma only impacts about 2,500 people in the US every year. It is most common among people who have lived or worked around asbestos. Peritoneal mesothelioma is even rarer. About a fifth of patients … Continue reading Misdiagnosis of Mesothelioma More Common with Cytology Alone »

New Surgical Technique May Support Long-Term Peritoneal Mesothelioma Survival

long-term peritoneal mesothelioma survival

One of the nation’s top mesothelioma doctors says long-term peritoneal mesothelioma survival is possible with a far-reaching new surgical technique. Dr. Paul Sugarbaker is a surgeon with the Washington Cancer Institute in Washington, DC. He has studied peritoneal mesothelioma for decades.  In a new report, he outlines a case of long-term peritoneal mesothelioma survival in a female patient. The patient had cytoreductive surgery. The surgery included resection of the colonic mesentery. This is tissue that is not normally part of peritoneal mesothelioma surgery.  The case report shows the patient is still cancer-free four years after surgery with an “excellent” quality of life.  The Challenge of Peritoneal Mesothelioma Every year, about 2,500 Americans receive a diagnosis of mesothelioma. Peritoneal mesothelioma accounts … Continue reading New Surgical Technique May Support Long-Term Peritoneal Mesothelioma Survival »

New “Real World” Study of Immunotherapy for Peritoneal Mesothelioma

immunotherapy for peritoneal meosthelioma

A new study from one of the nation’s top cancer centers supports the role of immunotherapy in peritoneal mesothelioma treatment. Immunotherapy is a treatment approach that aims to harness the body’s natural defense system to fight cancer.  Several immunotherapy drugs have been tested for pleural mesothelioma. Pleural mesothelioma affects the lungs. Last year, the FDA approved a new combination of immunotherapy drugs for the pleural form of asbestos cancer.  But there is less data on immunotherapy for peritoneal mesothelioma. Researchers at MD Anderson Cancer Center just released their findings on a class of immunotherapy drugs called immune checkpoint inhibitors (ICIs). They say it is the first “real-world evidence” of clinical outcomes with ICIs in peritoneal mesothelioma patients. Immune Checkpoint Inhibitors … Continue reading New “Real World” Study of Immunotherapy for Peritoneal Mesothelioma »

Peritoneal Mesothelioma Prognosis: Searching for New Factors

peritoneal mesothelioma prognosis

An international research study including patients from 11 countries may help reveal new and better ways to predict peritoneal mesothelioma prognosis.  Right now, doctors use three primary criteria to determine peritoneal mesothelioma prognosis. Those are how much cancer was in the abdomen at the time of surgery, how complete the surgery was, and the tumor grade.  But about 70 percent of people treated for peritoneal cancers like mesothelioma have recurrent disease. The goal of the new study is to find more prognostic factors. Knowing these factors could help doctors make better choices about which patients are most likely to benefit from cytoreductive surgery (CRS).  The CRS/HIPEC Procedure for Mesothelioma Peritoneal mesothelioma occurs on the lining of the abdomen. Peritoneal mesothelioma … Continue reading Peritoneal Mesothelioma Prognosis: Searching for New Factors »

Paclitaxel May Prevent Metastatic Peritoneal Mesothelioma in High Risk People

metastatic peritoneal mesothelioma

Administering the chemotherapy drug paclitaxel directly into the abdomen of people with mesothelioma might offer a way to prevent metastatic peritoneal mesothelioma. That is the premise of a recent article by Dr. Paul Sugarbaker in the Journal of Gastrointestinal Oncology. Dr. Sugarbaker is a global expert in peritoneal mesothelioma. He works at MedStar Washington Hospital in Washington, DC. Metastatic peritoneal mesothelioma is when mesothelioma cells spread. They move from their original spot to other parts of the abdomen. Paclitaxel can help prevent new tumors in people who already have some metastases. In his new article, Dr. Sugarbaker says the evidence suggests that it might also work to keep metastases from forming. Metastatic Peritoneal Mesothelioma Treatment Malignant mesothelioma is a cancer … Continue reading Paclitaxel May Prevent Metastatic Peritoneal Mesothelioma in High Risk People »

NIPEC Treatment: Is This the Key to Long-Term Mesothelioma Survival?

nipec treatment

A mesothelioma treatment called NIPEC may help people with peritoneal mesothelioma live longer than expected. In some cases, much longer. A recent study of 74 peritoneal mesothelioma patients showed a combination of cytoreductive surgery (CRS), HIPEC, and NIPEC works better than CRS/HIPEC alone. The study comes from one of the country’s foremost medical authorities on peritoneal mesothelioma. Dr. Paul Sugarbaker runs the Peritoneal Surface Malignancy Program at Washington Cancer Institute in Washington, DC.  Last year, Dr. Sugarbaker released results of a small study on NIPEC treatment for mesothelioma. Although that study included only six patients, the results were impressive enough to warrant further study.  This year’s larger NIPEC study is even more promising for people fighting mesothelioma. Similarities and DIfferences … Continue reading NIPEC Treatment: Is This the Key to Long-Term Mesothelioma Survival? »

Concerning CT Findings and Mesothelioma Prognosis

Concerning CT Findings

One of the nation’s top mesothelioma doctors says concerning CT findings may be one of the best ways to predict peritoneal mesothelioma outcomes.  Dr. Paul Sugarbaker is with MedStar Washington Hospital Center in Washington, DC. His newly published study compares 11 different concerning CT findings with outcomes in 100 mesothelioma patients.  Sugarbaker and his team found that the prognostic value of these 11 CT features is on a par with peritoneal cancer index (PCI) and cytoreduction (CC) score. It means that CT findings could become even more important for mesothelioma treatment planning.  CT Scans Reveal Information About Peritoneal Mesothelioma Peritoneal mesothelioma occurs on the lining around the abdomen. It is an aggressive and hard-to-treat cancer caused by exposure to asbestos. … Continue reading Concerning CT Findings and Mesothelioma Prognosis »

Spread of Peritoneal Mesothelioma Slows with Apatinib

spread of peritoneal mesothelioma

An investigational drug called apatinib may help stop the growth and spread of peritoneal mesothelioma. Chinese researchers recently tested the VEGF inhibitor on mice infected with human mesothelioma.  They found that the spread of peritoneal mesothelioma slowed way down in the presence of apatinib. The drug worked in the lab and in live mice with few serious side effects. If larger experiments confirm apatinib’s effectiveness, the next step could be trials in human mesothelioma patients.  Apatinib Blocks Blood Vessel Formation Apatinib is also known as Rivoceranib. It keeps cancer cells from using the protein VEGF. VEGF (vascular endothelial growth factor) allows tumors to spawn new blood vessels. A rich supply of fresh blood fuels the growth and spread of peritoneal … Continue reading Spread of Peritoneal Mesothelioma Slows with Apatinib »

Peritoneal Mesothelioma Survival Not Shortened by Organ Resection

peritoneal mesothelioma survival

A new study finds that organ resection during CRS/HIPEC surgery does not shorten peritoneal mesothelioma survival and may even help prolong it.  The new research included 174 peritoneal mesothelioma patients from cancer centers across the country. These patients had cytoreductive surgery followed by heated intraperitoneal chemotherapy (CRS/HIPEC).  About half of the patients also had at least one organ removed to help prevent mesothelioma recurrence. The goal of the new study was to determine what impact, if any, this practice has on peritoneal mesothelioma survival. The answer appears to be, not much.  CRS/HIPEC and Peritoneal Mesothelioma Survival About 20 percent of mesothelioma patients have the peritoneal variety. This type of mesothelioma occurs on the lining of the abdomen and can easily … Continue reading Peritoneal Mesothelioma Survival Not Shortened by Organ Resection »

Long Term Peritoneal Mesothelioma Survival with NIPEC

Long Term Peritoneal Mesothelioma Survival

A new report suggests that long term peritoneal mesothelioma survival may be possible with a treatment called NIPEC and the drug paclitaxel.  NIPEC stands for normothermic intraperitoneal chemotherapy. It is similar to the heated chemotherapy that many peritoneal mesothelioma patients now get. But NIPEC is delivered through a catheter over time and at room temperature.  The new article details the long term peritoneal mesothelioma survival of six patients on NIPEC with paclitaxel. It comes from one the nation’s leading experts in this form of mesothelioma, Paul Sugarbaker, MD.  Even though the sample size is small, Dr. Sugarbaker says the results are impressive enough to warrant further study.  HIPEC and Mesothelioma Treatment Peritoneal mesothelioma accounts for about 20 percent of mesothelioma … Continue reading Long Term Peritoneal Mesothelioma Survival with NIPEC »